January Therapeutics Announces Appointment of Dr. Steven Rosen as Chief Medical Advisor
January Therapeutics an oncology-focused biopharmaceutical research and development company, today announced the appointment of Steven Rosen, MD as Chief Medical Advisor. Dr. Rosen will support key aspects of clinical development for JNTX-101 program (Pro-drug albumin-encapsulated version of Gemcitabine – a backbone for many cancer treatments) and JNTX-104 (Pro-drug albumin-encapsulated version of 8-Chloro-Adenosine – a drug that has been used in patients with AML). Dr. Rosen will also lead January’s patient advocacy program.
Dr. Rosen is the Provost and Chief Scientific Officer of the City of Hope National Medical Center. In that role he leads the Beckman Research Institute and the Irell & Manella Graduate School of Biological Sciences. Dr. Rosen received both his BS and MD from Northwestern University where he also completed his residency. He has authored over 450 publications in the field of Oncology and serves on a number of oncology foundation boards including AACR, ASCO, and the Leukemia & Lymphoma Society.
“We are very pleased to welcome Dr. Steve Rosen to ” said Sam Ellis, CEO of Therapeutics. “His deep therapeutic knowledge combined with industry experience and advocacy for translational medicine in biotech will bring world class expertise to January.”
January Therapeutics is a biotechnology company focused on discovering novel therapeutics that leverage the proven clinical benefits of protein-based nanoparticle formulation. Their initial development programs are oncology focused, specifically related to therapeutics that treat sarcomas, ovarian, lung and other solid tumors.
This article was shared with Prittle Prattle News as a Press Release by PRNewswire.
